GSK3186899

• CAT Number: I020012
• CAS Number: 1972617-87-0
• Molecular Formula: C₁₉H₂₈F₃N₇O₃S
• Molecular Weight: 491.53
• Purity: ≥95%
• Target: Parasite
• IUPAC Name: 3,3,3-trifluoro-N-[4-[[3-[(2S)-2-methylmorpholin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl]amino]cyclohexyl]propane-1-sulfonamide
• InChI: InChI=1S/C19H28F3N7O3S/c1-12-11-29(7-8-32-12)17-15-10-23-18(25-16(15)26-27-17)24-13-2-4-14(5-3-13)28-33(30,31)9-6-19(20,21)22/h10,12-14,28H,2-9,11H2,1H3,(H2,23,24,25,26,27)/t12-,13?,14?/m0/s1
• InChIKey: RQWCISVRFNZHMJ-HSBZDZAISA-N
• SMILES: C[C@H]1CN(CCO1)C2=NNC3=NC(=NC=C32)NC4CCC(CC4)NS(=O)(=O)CCC(F)(F)F

GSK3186899（Cat No.:I020012）is a selective and potent inhibitor of the enzyme glycogen synthase kinase-3β (GSK-3β), which plays a crucial role in various cellular processes, including glycogen metabolism, gene expression, and cell cycle regulation. By inhibiting GSK-3β, GSK3186899 has potential therapeutic applications in treating diseases associated with abnormal GSK-3β activity, such as neurodegenerative disorders, cancer, and psychiatric conditions. This compound is being investigated for its ability to modulate signaling pathways involved in cell survival, differentiation, and inflammation, making it a promising candidate for drug development.

Reference

[1]. Wyllie S, et al. Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis. Nature. 2018 Aug;560(7717):192-197.